世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

バイオシミュレーション市場:製品毎(ソフトウェア、分子シミュレーション、内製、契約サービス)、用途毎(臨床試験、PKPD、ADME)、デリバリ毎(加入、所有)、エンドユーザ毎(バイオ企業、医薬品企業、CRO、法規制機関) - 2022年までの世界市場予測

Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2018年1月US$4,950
シングルユーザライセンス
182 215

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)のバイオシミュレーション市場に関する調査レポートです。

“Global biosimulation market projected to grow at a CAGR of 15.9%”

The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in 2017, at a CAGR of 15.9%. Increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the biosimulation market. On the other hand, market growth may be limited to a certain extent due to the lack of standardization for biosimulation solutions.

“Biosimulation services are expected to grow at the highest CAGR during the forecast period”

By product and service, the biosimulation market is segmented into software and services. The biosimulation services segment is projected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the recurring need for services such as data analysis, and consulting services.

“Ownership models segment is expected to dominate the market during the forecast period”

Based on the delivery model, the biosimulation market is segmented into ownership models and subscription models. The ownership models segment is expected to dominate the market during the forecast period. Buyers mainly opt for these delivery models due to the security benefits associated with them are the major factors that are supporting the growth of this delivery models segment.

“Europe to witness high growth during the forecast period”

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Europe is expected to register the highest CAGR during the forecast period. The growing focus on research-related funding activities by governments is expected to assist in the development of drug discovery and development process, thus driving the demand for biosimulation in the European region.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 62%; Tier 2 - 25%; Tier 3 - 13%.
- By Designation: C-level- 29%; D-level- 25%; Others-46%.
- By Region: North America-55%; Europe-24%; Asia-15%; RoW-6%.

List of companies profiled in the report

- Certara (US)
- Simulations Plus (US)
- Dassault Syst-mes (France)
- Schr-dinger (US)
- ACD/Labs (Canada)
- Chemical Computing Group (Canada)
- Physiomics (UK)
- Evidera (US)
- In silico biosciences (US)
- INOSIM Software (Germany)
- Insilico Biotechnology (Germany)
- LeadInvent Technologies (India)
- Rosa (US)
- Nuventra Pharma (US)
- Genedata (Switzerland)ssss

Research Coverage:

The report provides an overview of the biosimulation market. It aims at estimating the market size and future growth potential of this market across different segments such as product & service, applications, delivery model, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall biosimulation market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.



目次

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 MARKET STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 20
2.1 RESEARCH DATA 20
2.2 SECONDARY DATA 21
2.2.1 SECONDARY SOURCE 21
2.3 PRIMARY DATA 22
2.3.1 PRIMARY SOURCES 22
2.3.2 KEY INDUSTRY INSIGHTS 24
2.4 MARKET SIZE ESTIMATION 24
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.6 ASSUMPTIONS FOR THE STUDY 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 32
4.1 BIOSIMULATION MARKET OVERVIEW 32
4.2 BIOSIMULATION SOFTWARE MARKET, BY TYPE 32
4.3 GEOGRAPHIC ANALYSIS: BIOSIMULATION MARKET IN EUROPE,
BY END USER AND COUNTRY 33
4.4 BIOSIMULATION DRUG DEVELOPEMENT MARKET, BY TYPE 34

5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Increase in R&D investments in the pharmaceutical and biotechnology industries 36
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies 36
5.2.1.3 Technologically advanced QSP systems 36
5.2.1.4 Need to curtail drug discovery and development costs 37
5.2.1.5 Growth in the biologics and biosimilars markets 37
5.2.2 RESTRAINT 37
5.2.2.1 Lack of standardization 37
5.2.3 OPPORTUNITIES 38
5.2.3.1 Emerging applications 38
5.2.3.2 Increased use of personalized medicine 38
5.2.3.3 Use of biosimulation solution for pediatric drug development 38
5.2.4 CHALLENGES 39
5.2.4.1 Difficulty in matching the complexity of biological systems and processes 39
5.2.4.2 Shortage of biosimulation and modeling experts 39

6 BIOSIMULATION MARKET, BY PRODUCT & SERVICE 40
6.1 INTRODUCTION 41
6.2 SOFTWARE 42
6.2.1 PK/PD MODELING AND SIMULATION SOFTWARE 43
6.2.2 MOLECULAR MODELING AND SIMULATION SOFTWARE 45
6.2.3 PBPK MODELING AND SIMULATION SOFTWARE 47
6.2.4 TOXICITY PREDICTION SOFTWARE 48
6.2.5 TRIAL DESIGN SOFTWARE 49
6.2.6 OTHER BIOSIMULATION SOFTWARE 51
6.3 SERVICES 53
6.3.1 IN-HOUSE SERVICES 54
6.3.2 CONTRACT SERVICES 56

7 BIOSIMULATION MARKET, BY APPLICATION 58
7.1 INTRODUCTION 59
7.2 DRUG DEVELOPMENT 60
7.2.1 PRECLINICAL TESTING 62
7.2.1.1 PK/PD 64
7.2.1.2 ADME/Tox 65
7.2.2 CLINICAL TRIALS 67
7.3 DRUG DISCOVERY 69
7.3.1 TARGET IDENTIFICATION AND VALIDATION 70
7.3.2 LEAD IDENTIFICATION AND OPTIMIZATION 72
7.4 OTHER APPLICATIONS 74

8 BIOSIMULATION MARKET, BY DELIVERY MODEL 76
8.1 INTRODUCTION 77
8.2 SUBSCRIPTION MODELS 78
8.3 OWNERSHIP MODELS 80
-
9 BIOSIMULATION MARKET, BY END USER 82
9.1 INTRODUCTION 83
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 84
9.3 RESEARCH INSTITUTES 86
9.4 CONTRACT RESEARCH ORGANIZATIONS 88
9.5 REGULATORY AUTHORITIES 90
9.6 OTHER END USERS 92

10 BIOSIMULATION MARKET, BY REGION 94
10.1 INTRODUCTION 95
10.2 NORTH AMERICA 96
10.2.1 US 100
10.2.2 CANADA 105
10.3 EUROPE 109
10.3.1 GERMANY 114
10.3.2 UK 118
10.3.3 FRANCE 122
10.3.4 REST OF EUROPE (ROE) 126
10.4 ASIA 130
10.5 REST OF THE WORLD (ROW) 135

11 COMPETITIVE LANDSCAPE 140
11.1 OVERVIEW 140
11.2 MARKET RANKING ANALYSIS, 2016 141
11.3 COMPETITIVE SCENARIO 142
11.3.1 PRODUCT LAUNCHES AND APPROVALS 142
11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 142
11.3.3 ACQUISITIONS 143
11.3.4 EXPANSIONS 143

12 COMPANY PROFILES 144
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
12.1 CERTARA 144
12.2 SIMULATION PLUS 147
12.3 DASSAULT SYST-MES 151
12.4 SCHR-DINGER 154
12.5 ADVANCED CHEMISTRY DEVELOPMENT 157
12.6 CHEMICAL COMPUTING GROUP 159
12.7 ROSA 160
12.8 GENEDATA 161
12.9 PHYSIOMICS 163
12.10 EVIDERA 165
12.11 IN SILICO BIOSCIENCES 166
12.12 LEADINVENT TECHNOLOGIES 167
12.13 INOSIM SOFTWARE 168
12.14 NUVENTRA PHARMA 169
12.15 INSILICO BIOTECHNOLOGY 170

*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.

13 APPENDIX 171
13.1 INSIGHTS FORM INDUSTRY EXPERTS 171
13.2 DISCUSSION GUIDE 172
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 175
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 177
13.5 AVAILABLE CUSTOMIZATIONS 178
13.6 RELATED REPORTS 179
13.7 AUTHOR DETAILS 180

 

LIST OF TABLES

TABLE 1 BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION) 41
TABLE 2 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION) 42
TABLE 3 BIOSIMULATION SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION) 42
TABLE 4 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 43
TABLE 5 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 43
TABLE 6 PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY REGION,
2015-2022 (USD MILLION) 44
TABLE 7 NORTH AMERICA: PK/PD MODELING AND SIMULATION SOFTWARE MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 44
TABLE 8 EUROPE: PK/PD MODELING AND SIMULATION SOFTWARE MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 45
TABLE 9 MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET,
BY REGION, 2015-2022 (USD MILLION 45
TABLE 10 NORTH AMERICA: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015-2022 (USD MILLION) 46
TABLE 11 EUROPE: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 46
TABLE 12 PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY REGION,
2015-2022 (USD MILLION) 47
TABLE 13 NORTH AMERICA: PBPK MODELING AND SIMULATION SOFTWARE MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 47
TABLE 14 EUROPE: PBPK MODELING AND SIMULATION SOFTWARE MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 48
TABLE 15 TOXICITY PREDICTION SOFTWARE MARKET, BY REGION,
2015-2022 (USD MILLION) 48
TABLE 16 NORTH AMERICA: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 49
TABLE 17 EUROPE: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 49
TABLE 18 TRIAL DESIGN SOFTWARE MARKET, BY REGION, 2015-2022 (USD MILLION) 50
TABLE 19 NORTH AMERICA: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 50
TABLE 20 EUROPE: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 50
TABLE 21 OTHER BIOSIMULATION SOFTWARE MARKET, BY REGION,
2015-2022 (USD MILLION) 51
TABLE 22 NORTH AMERICA: OTHER BIOSIMULATION SOFTWARE MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 52
TABLE 23 EUROPE: OTHER BIOSIMULATION SOFTWARE MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 52
TABLE 24 BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION) 53
TABLE 25 BIOSIMULATION SERVICES MARKET, BY REGION, 2015-2022 (USD MILLION) 53
TABLE 26 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 54
TABLE 27 EUROPE: BIOSIMULATION SERVICES MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 54
TABLE 28 IN-HOUSE BIOSIMULATION SERVICES MARKET, BY REGION,
2015-2022 (USD MILLION) 55
TABLE 29 NORTH AMERICA: IN-HOUSE BIOSIMULATION SERVICES MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 55
TABLE 30 EUROPE: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 55
TABLE 31 CONTRACT BIOSIMULATION SERVICES MARKET, BY REGION,
2015-2022 (USD MILLION) 56
TABLE 32 NORTH AMERICA: CONTRACT BIOSIMULATION SERVICES MARKET,
BY COUNTRY, 2015-2022 (USD MILLION) 56
TABLE 33 EUROPE: CONTRACT BIOSIMULATION SERVICES MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 57
TABLE 34 BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 59
TABLE 35 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY TYPE,
2015-2022 (USD MILLION) 60
TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION,
2015-2022 (USD MILLION) 61
TABLE 37 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT,
BY COUNTRY, 2015-2022 (USD MILLION) 61
TABLE 38 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT,
BY COUNTRY, 2015-2022 (USD MILLION) 61
TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2015-2022 (USD MILLION) 62
TABLE 40 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY REGION,
2015-2022 (USD MILLION ) 63
TABLE 41 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY COUNTRY, 2015-2022 (USD MILLION) 63
TABLE 42 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2015-2022 (USD MILLION) 63
TABLE 43 BIOSIMULATION MARKET FOR PK/PD, BY REGION, 2015-2022 (USD MILLION) 64
TABLE 44 NORTH AMERICA: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY,
2015-2022 (USD MILLION) 65
TABLE 45 EUROPE: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY,
2015-2022 (USD MILLION) 65
TABLE 46 BIOSIMULATION MARKET FOR ADME/TOX, BY REGION, 2015-2022 (USD MILLION) 66
TABLE 47 NORTH AMERICA: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY,
2015-2022 (USD MILLION) 66
TABLE 48 EUROPE: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY,
2015-2022 (USD MILLION) 67
TABLE 49 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY REGION,
2015-2022 (USD MILLION) 67
TABLE 50 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS,
BY COUNTRY, 2015-2022 (USD MILLION) 68
TABLE 51 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY,
2015-2022 (USD MILLION) 68
TABLE 52 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY TYPE,
2015-2022 (USD MILLION ) 69
TABLE 53 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION,
2015-2022 (USD MILLION) 69
TABLE 54 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY,
BY COUNTRY, 2015-2022 (USD MILLION) 70
TABLE 55 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY,
2015-2022 (USD MILLION) 70
TABLE 56 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND OPTIMIZATION,
BY REGION, 2015-2022 (USD MILLION) 71
TABLE 57 NORTH AMERICA: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015-2022 (USD MILLION) 71
TABLE 58 EUROPE: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015-2022 (USD MILLION) 72
TABLE 59 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION,
BY REGION, 2015-2022 (USD MILLION) 72
TABLE 60 NORTH AMERICA: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015-2022 (USD MILLION) 73
TABLE 61 EUROPE: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015-2022 (USD MILLION) 73
TABLE 62 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION,
2015-2022 (USD MILLION ) 74
TABLE 63 NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2015-2022 (USD MILLION) 74
TABLE 64 EUROPE: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015-2022 (USD MILLION) 75
TABLE 65 GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL,
2015-2022 (USD MILLION) 77
TABLE 66 GLOBAL BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS,
BY REGION, 2015-2022 (USD MILLION) 78
TABLE 67 NORTH AMERICA: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS,
BY COUNTRY, 2015-2022 (USD MILLION) 79
TABLE 68 EUROPE: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS,
BY COUNTRY, 2015-2022 (USD MILLION) 79
TABLE 69 GLOBAL BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY REGION,
2015-2022 (USD MILLION) 80
TABLE 70 NORTH AMERICA: BIOSIMULATION MARKET FOR OWNERSHIP MODELS,
BY COUNTRY, 2015-2022 (USD MILLION) 80
TABLE 71 EUROPE: BIOSIMULATION MARKET FOR OWNERSHIP MODELS,
BY COUNTRY, 2015-2022 (USD MILLION) 81
TABLE 72 BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 83
TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2015-2022 (USD MILLION) 84
TABLE 74 NORTH AMERICA: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015-2022 (USD MILLION) 85
TABLE 75 EUROPE: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015-2022 (USD MILLION) 85
TABLE 76 BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY REGION,
2015-2022 (USD MILLION) 86
TABLE 77 NORTH AMERICA: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2015-2022 (USD MILLION) 87
TABLE 78 EUROPE: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2015-2022 (USD MILLION) 87
TABLE 79 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2015-2022 (USD MILLION) 88
TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015-2022 (USD MILLION) 89
TABLE 81 EUROPE: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015-2022 (USD MILLION) 89
TABLE 82 BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY REGION,
2015-2022 (USD MILLION) 90
TABLE 83 NORTH AMERICA: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES,
BY COUNTRY, 2015-2022 (USD MILLION) 91
TABLE 84 EUROPE: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES,
BY COUNTRY, 2015-2022 (USD MILLION) 91
TABLE 85 BIOSIMULATION MARKET FOR OTHER END USERS, BY REGION,
2015-2022 (USD MILLION) 92
TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER END USERS,
BY COUNTRY, 2015-2022 (USD MILLION) 93
TABLE 87 EUROPE: BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY,
2015-2022 (USD MILLION) 93
TABLE 88 BIOSIMULATION MARKET, BY REGION, 2015-2022 (USD MILLION) 95
TABLE 89 NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY,
2015-2022 (USD MILLION) 97
TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 97
TABLE 91 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2015-2022 (USD MILLION) 97
TABLE 92 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2015-2022 (USD MILLION) 98
TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2015-2022 (USD MILLION) 98
TABLE 94 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION) 99
TABLE 95 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2015-2022 (USD MILLION) 99
TABLE 96 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION) 99
TABLE 97 NORTH AMERICA: BIOSIMULATION MARKET, BY DELIVERY MODEL,
2015-2022 (USD MILLION) 100
TABLE 98 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER,
2015-2022 (USD MILLION) 100
TABLE 99 US: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 101
TABLE 100 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION) 102
TABLE 101 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION) 102
TABLE 102 US: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 102
TABLE 103 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015-2022 (USD MILLION) 103
TABLE 104 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2015-2022 (USD MILLION) 103
TABLE 105 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 103
TABLE 106 US: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION) 104
TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 104
TABLE 108 CANADA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 105
TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2015-2022 (USD MILLION) 105
TABLE 110 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2015-2022 (USD MILLION) 106
TABLE 111 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 106
TABLE 112 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 106
TABLE 113 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2015-2022 (USD MILLION) 107
TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 107
TABLE 115 CANADA: BIOSIMULATION MARKET, BY DELIVERY MODEL,
2015-2022 (USD MILLION) 108
TABLE 116 CANADA: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 108
TABLE 117 EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2015 109
TABLE 118 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2015-2022 (USD MILLION) 111
TABLE 119 EUROPE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 111
TABLE 120 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2015-2022 (USD MILLION) 111
TABLE 121 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2015-2022 (USD MILLION) 112
TABLE 122 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 112
TABLE 123 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 112
TABLE 124 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2015-2022 (USD MILLION) 113
TABLE 125 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 113
TABLE 126 EUROPE: BIOSIMULATION MARKET, BY DELIVERY MODEL,
2015-2022 (USD MILLION) 113
TABLE 127 EUROPE: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 114
TABLE 128 BIOTECHNOLOGY INDUSTRY IN GERMANY (2009 VS. 2016) 114
TABLE 129 GERMANY: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 115
TABLE 130 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2015-2022 (USD MILLION) 115
TABLE 131 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE,
2015-2022 (USD MILLION) 115
TABLE 132 GERMANY: BIOSIMULATION MARKET, BY APPLICATION,
2015-2022 (USD MILLION) 116
TABLE 133 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 116
TABLE 134 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2015-2022 (USD MILLION) 116
TABLE 135 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 117
TABLE 136 GERMANY: BIOSIMULATION MARKET, BY DELIVERY MODEL,
2015-2022 (USD MILLION) 117
TABLE 137 GERMANY: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 117
TABLE 138 UK: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 119
TABLE 139 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION) 119
TABLE 140 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION) 119
TABLE 141 UK: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 120
TABLE 142 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 120
TABLE 143 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2015-2022 (USD MILLION) 120
TABLE 144 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 121
TABLE 145 UK: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION) 121
TABLE 146 UK: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 121
TABLE 147 FRANCE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 122
TABLE 148 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2015-2022 (USD MILLION) 123
TABLE 149 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2015-2022 (USD MILLION) 123
TABLE 150 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 123
TABLE 151 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 124
TABLE 152 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2015-2022 (USD MILLION) 124
TABLE 153 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 124
TABLE 154 FRANCE: BIOSIMULATION MARKET, BY DELIVERY MODEL,
2015-2022 (USD MILLION) 125
TABLE 155 FRANCE: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 125
TABLE 156 ROE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 126
TABLE 157 ROE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION) 127
TABLE 158 ROE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION) 127
TABLE 159 ROE: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 127
TABLE 160 ROE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 128
TABLE 161 ROE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2015-2022 (USD MILLION) 128
TABLE 162 ROE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 128
TABLE 163 ROE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION) 129
TABLE 164 ROE: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 129
TABLE 165 ASIA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 132
TABLE 166 ASIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION) 132
TABLE 167 ASIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION) 132
TABLE 168 ASIA: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 133
TABLE 169 ASIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 133
TABLE 170 ASIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2015-2022 (USD MILLION) 133
TABLE 171 ASIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 134
TABLE 172 ASIA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION) 134
TABLE 173 ASIA: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 134
TABLE 174 ROW: BIOSIMULATION MARKET, BY PRODUCT & SERVICE,
2015-2022 (USD MILLION) 137
TABLE 175 ROW: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015-2022 (USD MILLION) 137
TABLE 176 ROW: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015-2022 (USD MILLION) 137
TABLE 177 ROW: BIOSIMULATION MARKET, BY APPLICATION, 2015-2022 (USD MILLION) 138
TABLE 178 ROW: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 138
TABLE 179 ROW: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2015-2022 (USD MILLION) 138
TABLE 180 ROW: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2015-2022 (USD MILLION) 139
TABLE 181 ROW: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015-2022 (USD MILLION) 139
TABLE 182 ROW: BIOSIMULATION MARKET, BY END USER, 2015-2022 (USD MILLION) 139
TABLE 183 RANK OF COMPANIES IN THE GLOBAL BIOSIMULATION MARKET, 2016 141
TABLE 184 PRODUCT LAUNCHES AND APPROVALS 142
TABLE 185 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 142
TABLE 186 ACQUISITIONS 143
TABLE 187 EXPANSIONS 143

 

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN: BIOSIMULATION MARKET 20
FIGURE 2 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 23
FIGURE 3 MARKET ESTIMATION: BOTTOM-UP APPROACH 25
FIGURE 4 GLOBAL MARKET SIZE OF THE BIOSIMULATION MARKET: TOP-DOWN APPROACH 25
FIGURE 5 DATA TRIANGULATION METHODOLOGY 26
FIGURE 6 BIOSIMULATION SOFTWARE TO DOMINATE THE BIOSIMULATION MARKET
IN 2017 AND 2022 28
FIGURE 7 DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION APPLICATIONS MARKET IN 2017 AND 2022 29
FIGURE 8 SUBSCRIPTION MODEL SEGMENT TO DOMINATE THE DELIVERY MODEL SEGMENT OF BIOSIMULATION MARKET IN 2017 AND 2022 29
FIGURE 9 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE BIOSIMULATION END-USER MARKET 30
FIGURE 10 EUROPE TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
(2017-2022) 31
FIGURE 11 INCREASE IN R&D INVESTMENTS IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE THE GROWTH OF THE MARKET 32
FIGURE 12 PK/PD MODELING AND SIMULATION SOFTWARE TO ACCOUNT FOR THE LARGEST MARKET SIZE IN 2017 AND 2022 32
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN EUROPE IN 2017 33
FIGURE 14 PRECLINICAL TESTING TO WITNESS HIGH GROWTH FROM 2017 TO 2022 34
FIGURE 15 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 16 SOFTWARE SEGMENT TO DOMINATE THE BIOSIMULATION MARKET IN 2017 41
FIGURE 17 DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION MARKET DURING THE FORECAST PERIOD 59
FIGURE 18 OWNERSHIP MODELS SEGMENT TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD 77
FIGURE 19 BIOSIMULATION MARKET, BY END USER, 2017 VS. 2022 (USD MILLION) 83
FIGURE 20 BIOSIMULATION MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 95
FIGURE 21 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT 96
FIGURE 22 EUROPE: BIOSIMULATION MARKET SNAPSHOT 110
FIGURE 23 ASIA: BIOSIMULATION MARKET SNAPSHOT 131
FIGURE 24 ROW: BIOSIMULATION MARKET SNAPSHOT 136
FIGURE 25 MARKET EVOLUTION FRAMEWORK 141
FIGURE 26 SIMULATION PLUS: COMPANY SNAPSHOT (2016) 147
FIGURE 27 DASSAULT SYST-MES: COMPANY SNAPSHOT (2016) 151
FIGURE 28 PHYSIOMICS : COMPANY SNAPSHOT (2017) 163

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る